<H1>Chapter DOI: 10.1007/978-1-60327-829-4_8<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>44</td></tr><tr><td>Springer references</td><td>0</td></tr><tr><td>Non Springer references</td><td>44</td></tr><tr><td>BibStructured Count</td><td width="10%">44</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>33</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>0</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>0</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_8</td><td>BibArticle</td><td>Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;168:9&#8211;12.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(05)64820-3>10.1016/S0022-5347(05)64820-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2_8</td><td>BibArticle</td><td>Huggins C. Effect of orchiectomy and irradiation on cancer of the prostate. Ann Surg 1942;115:1192&#8211;200.</td><td><a href=http://dx.doi.org/10.1097/00000658-194206000-00030>10.1097/00000658-194206000-00030</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3_8</td><td>BibArticle</td><td>Small EJ, Ryan CJ. The case for secondary hormonal therapies in the chemotherapy age. J Urol 2006;176:S66&#8211;71.</td><td><a href=http://dx.doi.org/10.1016/j.juro.2006.06.071>10.1016/j.juro.2006.06.071</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4_8</td><td>BibArticle</td><td>Seidenfeld J, Samson DJ, Hasselblad V et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132:566&#8211;77.</td><td><a href=http://dx.doi.org/10.7326/0003-4819-132-7-200004040-00009>10.7326/0003-4819-132-7-200004040-00009</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5_8</td><td>BibArticle</td><td>Roach M, 3rd, Izaguirre A. Goserelin acetate in combination with radiotherapy for prostate cancer. Expert Opin Pharmacother 2007;8:257&#8211;64.</td><td><a href=http://dx.doi.org/10.1517/14656566.8.2.257>10.1517/14656566.8.2.257</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6_8</td><td>BibArticle</td><td>Loblaw DA, Mendelson DS, Talcott JA et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004;22:2927&#8211;41.</td><td><a href=http://dx.doi.org/10.1200/JCO.2004.04.579>10.1200/JCO.2004.04.579</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7_8</td><td>BibArticle</td><td>Janknegt RA, Abbou CC, Bartoletti R et al. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993;149:77&#8211;82; discussion 3.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR8_8</td><td>BibArticle</td><td>Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33&#8211;9.</td><td><a href=http://dx.doi.org/10.1038/nm972>10.1038/nm972</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9_8</td><td>BibArticle</td><td>Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993;149:607&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR10_8</td><td>BibArticle</td><td>Schellhammer PF, Venner P, Haas GP et al. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 1997;157:1731&#8211;5.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(01)64846-8>10.1016/S0022-5347(01)64846-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11_8</td><td>BibArticle</td><td>Kassouf W, Tanguay S, Aprikian AG. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol 2003;169:1742&#8211;4.</td><td><a href=http://dx.doi.org/10.1097/01.ju.0000057795.97626.66>10.1097/01.ju.0000057795.97626.66</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12_8</td><td>BibArticle</td><td>Bhanalaph T, Varkarakis MJ, Murphy GP. Current status of bilateral adrenalectomy or advanced prostatic carcinoma. Ann Surg 1974;179:17&#8211;23.</td><td><a href=http://dx.doi.org/10.1097/00000658-197401000-00004>10.1097/00000658-197401000-00004</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13_8</td><td>BibArticle</td><td>Huggins C, Bergenstal DM. Inhibition of human mammary and prostatic cancers by adrenalectomy. Cancer Res 1952;12:134&#8211;41.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR14_8</td><td>BibArticle</td><td>Fakih M, Johnson CS, Trump DL. Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology 2002;60:553&#8211;61.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(02)01741-7>10.1016/S0090-4295(02)01741-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15_8</td><td>BibArticle</td><td>Nishimura K, Nonomura N, Satoh E et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 2001;93:1739&#8211;46.</td><td><a href=http://dx.doi.org/10.1093/jnci/93.22.1739>10.1093/jnci/93.22.1739</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16_8</td><td>BibArticle</td><td>Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res 2006;12:3003&#8211;9.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-05-2085>10.1158/1078-0432.CCR-05-2085</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17_8</td><td>BibArticle</td><td>Yano A, Fujii Y, Iwai A, Kawakami S, Kageyama Y, Kihara K. Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells. Clin Cancer Res 2006;12:6012&#8211;7.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-06-0749>10.1158/1078-0432.CCR-06-0749</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18_8</td><td>BibArticle</td><td>Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756&#8211;64.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR19_8</td><td>BibArticle</td><td>Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17:2506&#8211;13.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR20_8</td><td>BibArticle</td><td>Small EJ, Meyer M, Marshall ME et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 2000;18:1440&#8211;50.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR21_8</td><td>BibArticle</td><td>Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson RL. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 1995;76:96&#8211;100.</td><td><a href=http://dx.doi.org/10.1002/1097-0142(19950701)76:1&lt;96::AID-CNCR2820760114&gt;3.0.CO;2-E>10.1002/1097-0142(19950701)76:1&lt;96::AID-CNCR2820760114&gt;3.0.CO;2-E</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22_8</td><td>BibArticle</td><td>Sartor O, Cooper M, Weinberger M et al. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of &#8220;hormone-refractory&#8221; prostate cancer. J Natl Cancer Inst 1994;86:222&#8211;7.</td><td><a href=http://dx.doi.org/10.1093/jnci/86.3.222>10.1093/jnci/86.3.222</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23_8</td><td>BibArticle</td><td>Abratt RP, Brune D, Dimopoulos MA et al. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol 2004;15:1613&#8211;21.</td><td><a href=http://dx.doi.org/10.1093/annonc/mdh429>10.1093/annonc/mdh429</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24_8</td><td>BibArticle</td><td>Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994;330:263&#8211;72.</td><td><a href=http://dx.doi.org/10.1056/NEJM199401273300407>10.1056/NEJM199401273300407</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25_8</td><td>BibArticle</td><td>Lamberts SW, Bons EG, Bruining HA, de Jong FH. Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells. J Pharmacol Exp Ther 1987;240:259&#8211;64.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR26_8</td><td>BibArticle</td><td>Small EJ, Baron A, Bok R. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer 1997;80:1755&#8211;9.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1097-0142(19971101)80:9&lt;1755::AID-CNCR9&gt;3.0.CO;2-D>10.1002/(SICI)1097-0142(19971101)80:9&lt;1755::AID-CNCR9&gt;3.0.CO;2-D</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27_8</td><td>BibArticle</td><td>Small EJ, Baron AD, Fippin L, Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997;157:1204&#8211;7.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(01)64924-3>10.1016/S0022-5347(01)64924-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28_8</td><td>BibArticle</td><td>Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol 2002;168:542&#8211;5.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(05)64675-7>10.1016/S0022-5347(05)64675-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29_8</td><td>BibArticle</td><td>Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL. Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004;10:2584&#8211;6.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-03-0605>10.1158/1078-0432.CCR-03-0605</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30_8</td><td>BibArticle</td><td>Ryan CJ, Halabi S, Ou SS, Vogelzang NJ, Kantoff P, Small EJ. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Clin Cancer Res 2007;13:2030&#8211;7.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-06-2344>10.1158/1078-0432.CCR-06-2344</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31_8</td><td>BibArticle</td><td>Ryan C, Rosenberg JR, Lin A, Valiente A, Kim J, Small EJ. Phase I evaluation of abiraterone acetate (CB7630), a 17 alpha hydroxylase C17,20-Lyase inhibitor in androgen-independent prostate cancer (AiPC). ASCO Annual Meeting Proceedings J Clin Oncol 2007;25:5064.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR32_8</td><td>BibArticle</td><td>Attard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26:4563&#8211;71.</td><td><a href=http://dx.doi.org/10.1200/JCO.2007.15.9749>10.1200/JCO.2007.15.9749</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33_8</td><td>BibArticle</td><td>De Bono JGA, Reid AH, Parker C, Dowsett M, Mollife R, Yap TA, Molina A, Lee G, Dearnaley D. Anti-tumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC). ASCO Annual Meeting Proceedings J Clin Oncol 2008;26:5005.</td><td><a href=http://dx.doi.org/10.1200/JCO.2008.19.2161>10.1200/JCO.2008.19.2161</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34_8</td><td>BibArticle</td><td>Danila DDER, Morris MJ, Slovin SF, Schwartz LH, Farmer K, Anand A, Haqq C, Fleisher M, Scher HI. Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy. ASCO Annual Meeting Proceedings J Clin Oncol 2008;26:5019.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR44_8</td><td>BibArticle</td><td>Dreicer R, Agus DB, MacVicar GR et al. Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant, metastatic prostate cancer: a phase I/II, open-label study. In Proceedings of the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium; 2010 Mar 5&#8211;7; San Francisco. ASCO; 2010. Abstract 103.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1097-0142(20000215)88:4&lt;825::AID-CNCR13&gt;3.0.CO;2-N>10.1002/(SICI)1097-0142(20000215)88:4&lt;825::AID-CNCR13&gt;3.0.CO;2-N</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35_8</td><td>BibArticle</td><td>Kitahara S, Umeda H, Yano M et al. Effects of intravenous administration of high dose-diethylstilbestrol diphosphate on serum hormonal levels in patients with hormone-refractory prostate cancer. Endocr J 1999;46:659&#8211;64.</td><td><a href=http://dx.doi.org/10.1507/endocrj.46.659>10.1507/endocrj.46.659</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36_8</td><td>BibArticle</td><td>Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology 1998;52:257&#8211;60.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(98)00173-3>10.1016/S0090-4295(98)00173-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37_8</td><td>BibArticle</td><td>Small EJ, Frohlich MW, Bok R et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 2000;18:3595&#8211;603.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR38_8</td><td>BibArticle</td><td>Oh WK, Kantoff PW, Weinberg V et al. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol 2004;22:3705&#8211;12.</td><td><a href=http://dx.doi.org/10.1200/JCO.2004.10.195>10.1200/JCO.2004.10.195</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39_8</td><td>BibArticle</td><td>Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS. Secondary hormonal therapy for advanced prostate cancer. J Urol 2006;175:27&#8211;34.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(05)00034-0>10.1016/S0022-5347(05)00034-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40_8</td><td>BibArticle</td><td>Langley RE, Godsland IF, Kynaston H et al. Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer. BJU Int 2008;102:442&#8211;5.</td><td><a href=http://dx.doi.org/10.1111/j.1464-410X.2008.07583.x>10.1111/j.1464-410X.2008.07583.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41_8</td><td>BibArticle</td><td>Hudes G, Einhorn L, Ross E et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a hoosier oncology group and fox chase network phase III trial. J Clin Oncol 1999;17:3160&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR42_8</td><td>BibArticle</td><td>Osborn JL, Smith DC, Trump DL. Megestrol acetate in the treatment of hormone refractory prostate cancer. Am J Clin Oncol 1997;20:308&#8211;10.</td><td><a href=http://dx.doi.org/10.1097/00000421-199706000-00021>10.1097/00000421-199706000-00021</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43_8</td><td>BibArticle</td><td>Dawson NA, Conaway M, Halabi S et al. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. Cancer 2000;88:825&#8211;34.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1097-0142(20000215)88:4&lt;825::AID-CNCR13&gt;3.0.CO;2-N>10.1002/(SICI)1097-0142(20000215)88:4&lt;825::AID-CNCR13&gt;3.0.CO;2-N</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>